Current Capabilities
Protein Analyses
Protein expression
RNA Analyses
Gene expression
DNA Analyses
Mutation or SNP (genetic)
Methylation (epigenetic)
Microbiome Analyses
Abundance and species
Healthy or pathogens
Skin health assessment
Skin disease complication
Research Use Only Assay
Atopic Dermatitis (AD) vs. Psoriasis (PS)
Confirm the inflammatory signature of clinical trial participants prior to enrollment. AD vs. PS differentiates Atopic Dermatitis from Psoriasis and Others with an AUC of > 0.95
Atopic Dermatitis (AD) vs. Psoriasis (PS)
Confirm the inflammatory signature of clinical trial participants prior to enrollment. AD vs. PS differentiates Atopic Dermatitis from Psoriasis and Others with an AUC of > 0.95
Atopic dermatitis (AD) and Psoriasis (PS) exist on a spectrum of inflammation and often exhibit common clinical and histologic features, making them difficult to distinguish visually.3 AD is the most common type of eczema, affecting approximately 10% of the US population, approximately 9.6 million children and 16.5 million adults.1 PS affects more than 3% of the US adult population, nearly 7.5 million US adults.2
The DermTech Smart Sticker™ enables non-invasive collection of epidermal samples from lesional skin for subsequent gene expression analysis. The AD vs PS assay offers the ability to differentiate the two most common inflammatory diseases using a molecular signature of four key genes.
The ability to distinguish these two inflammatory conditions provides a valuable tool for biomarker-driven disease differentiation and confirmation prior to clinical trial enrollment and can be utilized for the personalized treatment of AD and PS patients in a clinical trial setting.
For Research Use Only under an IRB Approved Protocol
Send us a message
Click the contact us button and drop us a line. We'll be in touch shortly.
Get In Touch
Partner with DermTech today.